Dan Aronowitz

Many of you may have seen the February 5, 2024 Wall Street Journal article (here) describing the new lawsuit filed against Johnson & Johnson accusing the company of mismanaging its workers’ prescription-drug benefits. The new complaint, a copy of which can be found here, arguably represents a new direction in ERISA liability litigation, perhaps the next big thing after all of the ERISA excess fee litigation. In the following guest post, Dan Aronowitz, President of Encore [formerly Euclid] Fiduciary, examines the new lawsuit and assesses what it may represent. He also considers the company’s defenses as well as the need for a vigorous response to lawsuits of this kind. A version of this article previously was published on the Fid Guru Blog. I would like to thank Dan for allowing me to publish his article on this site. I welcome guest post submissions from responsible authors on topics of interest to this site’s readers. Please contact me directly if you would like to submit a guest post. Here is Dan’s article.Continue Reading Guest Post: Flipping the Script on the New Excess Health Plan Fee Case Against Johnson & Johnson